Vaccines Market

Vaccines Market Overview

The global Vaccines Market size was valued at USD 83.38 billion in 2024 and is predicted to reach USD 115.08 billion by 2030 with a CAGR of 5.5% from 2025-2030.

Some of the factors that propels the vaccines market include improvement in aging population, higher chronic diseases prevalence, and high medical expenditure. Besides, some of the significant players are choosing different business strategy such as mergers, joint ventures, and developing new products for sustaining its grip in the global market. However, the growth of the market is affected due to high regulatory norms. In contrast, messenger ribonucleic acid (mRNA) immunization is anticipated to open immense opportunities in the market in the near future.

Boosting Aging Population Fuels Market Growth

The demand for vaccination is increasing because of the aging population, as aged people easily acquire infections and suffer from diseases such as influenza, pneumonia, and shingles due to weakened immunity. Population aged 65 years and more is anticipated to increase to 16% in 2050 from the current 10% in 2022 by World Population Prospect 2022. Such increase in population raises the vaccines market demand for preventive measures that curb infections that boost the industry.

Increasing Chronic Disease Drives Market Growth

Growing incidents of chronic conditions such as diabetes, cardiovascular diseases and respiratory disorders and others compromises the strength of the human immune system further increasing the vulnerabilities of patients for infections such as flu, pneumonia hepatitis, and more. Such amplified vulnerability encourages service providers to immunize patients at the earliest since vaccination is perceived as a preventable measure that further propels the industry. The World Health Organization (WHO) reports 20 million new cancer cases in 2022, predicted to rise to 35 million by 2050 marking an increase of 77% within the time span of three decades. 

Rising Healthcare Expenditure Bolster Market Growth

Rising healthcare expenditures boosts the vaccines market while enabling investment in immunization programs, research and infrastructure development. This increasing focus towards government spending allows healthcare organizations to expand access to immunization as preventative measure. The CMS report that healthcare spendings grew by 7.3% in 2023, reaching USD 4.9 trillion or USD 14,570 per person in 2024. In contrast, In Canda as per CIHI, healthcare spending is expected to reach USD 372 billion or USD 9,054 per Canadian showing a 5.7% increase. Such increased healthcare spendings drives research and innovation in the domain of immunization that boost the market.

Intricate Guidelines Hinders Market Growth

The complex stringent regulations and guidelines associated with the industry hinders the vaccines market growth. The presence of regulatory bodies such as the Food and Drug Administration (FDA) and World Health Organization (WHO) possess stringent clinical trials, post market surveillance and approval requirements to ensure vaccine safety due to that the approval process delays creating barriers.

Introduction of mRNA Vaccines Creates Opportunities

Introduction of mRNA vaccines is anticipated to open the doors for the growth of the immunization industry in the future years. It can be adapted to change the product quickly and be effective against a mutating pathogen and even the next pandemics. In a recent announcement, the Russian Health Ministry reported developing cancer mRNA immunisation that is scheduled to come to the market early in 2025. The innovation targets to improve the immunity system in fighting and killing the cancer cells.

Market Segmentations and Scope of the Study 

The vaccines market report is segmented on the basis of technology platform, disease indication, route of administration, target population, end user, and region. Based on technology platform, the market is categorized into live attenuated vaccines, inactivated vaccines, subunit and recombinant vaccines, polysaccharide and conjugate vaccines, toxoid vaccines, viral vector vaccines, and messenger RNA vaccines.

Based on disease indication, the market is segmented into respiratory diseases, pediatric diseases, and other significant diseases. The respiratory diseases segment is further divided into influenza vaccines, pneumococcal vaccines, Covid-19 vaccines, and respiratory syncytial virus vaccines. The pediatric diseases segment includes diphtheria tetanus pertussis vaccines, measles mumps rubella vaccines, polio vaccines, varicella vaccines, and rotavirus vaccines. The other significant diseases segment is categorized into human papillomavirus vaccines, meningococcal vaccines, hepatitis vaccines, and herpes zoster vaccines.

Based on route of administration, the market is divided into intramuscular injection, subcutaneous injection, oral administration, and intranasal administration. Based on target population, the market is segmented into pediatric vaccines, adult and adolescent vaccines, and geriatric vaccines. Based on end user, the market is categorized into public sector market and private sector market. Regional analysis of all the aforementioned segments covers North America, Europe, Asia-Pacific, and Row.

Geographical Analysis

North America region leads the vaccines market and is expected to maintain its dominance in the vaccine market during the forecast period due to the rise in cancer-related diseases that heightened the demand for both preventive and curative solutions. The risk factor increases the industry and reduces the disease burden. 

According to the 2024 publication by the National Cancer Institute report, the United States experienced an estimate of total cancer cases 18.1 million in the year 2022 and projects an increase with a growth rate of 43.6% jumping to 26 million by the year 2040. This increasing prevalence of disease burden prompts the usage of vaccines to avoid infections resulting in boot in the industry. 

Moreover, the increasing geriatric population is driving the vaccines market because of the increased demand for immunization against age-related diseases and infections. Older people's experiences weakened immune systems make them more susceptible to conditions such as influenza, pneumonia, and shingles, thereby requiring disease-specific immunization as preventive measures. 

According to the report of Pan American Health Organisation in 2022, the population aged 60 years and more in Mexico in 2022 is estimated to be 15.12 million while this figure is estimated to increase to 31.50 million by 2050 with a rise of 108%. The increasing population prompts vaccines for infection control that boost the market. 

Vaccines market in Asia-Pacific region continues to increase steadily, due to the increased spending on health care calls for investment in research and vaccine distribution infrastructure to buy and distribute immunization widely, increasing areas of access and areas of coverage. 

According to the report issued by World Health Organization 2024, health care expenditure per capita in China increased from USD 504.11 in 2018 to USD 672.45 in 2022, thus registering an increase of 33.44% within 4 years. Such increased in healthcare spendings drives research and development that ultimately fuels the market. 

Besides, the increasing diabetes cases in India is also growing the immunization market because of the compromised immunity of diabetic people, that compels vaccines as a measure to avoid infections such as pneumococcal infections and hepatitis B. According to the report published by the International Diabetes Federation 2024, in 2021, the number of people diagnosed with diabetes summed 74.19 million and is projected to increase up to 92.97 million in 2030, thus recording a growth of 25.3%.

Competitive Landscape

Various key players operating in the vaccines industry are Biofarma,Merck & Co., Inc. (MSD), Pfizer Inc., GlaxoSmithKline plc (GSK), Sanofi S.A., Johnson & Johnson, Moderna, Inc., BioNTech SE, CSL Seqirus, Sinopharm Group / CNBG, Novavax, Inc., Serum Institute of India Pvt. Ltd. (SII), Sinovac Biotech Ltd., Bharat Biotech International Ltd., Biological E. Limited (BE), Lonza Group AG, Catalent, Inc., CanSino Biologics Inc., WuXi Vaccines, Bavarian Nordic A/S, Panacea Biotec Ltd. and others. These companies are adopting various strategies such as collaboration and expansion to maintain their dominance in immunization industry.

For instance, in November 2025, Merck & Co., Inc. (MSD) expanded its vaccine research and development initiatives by strengthening its immunization portfolio focused on infectious diseases and next-generation vaccine technologies. The company also increased investments in advanced biologics manufacturing and global vaccine accessibility programs to support rising demand for preventive healthcare solutions.

Besides, in October 2025, Pfizer Inc. enhanced its global vaccine innovation strategy through the development of advanced mRNA-based vaccines and combination immunization programs targeting respiratory and infectious diseases. The company further emphasized expanding manufacturing capacity and strengthening global vaccine supply chains to improve immunization coverage across developed and emerging markets.

Furthermore, in September 2025, GlaxoSmithKline plc (GSK) strengthened its vaccine portfolio by advancing research programs for respiratory syncytial virus, influenza, and adult immunization products. The company also focused on improving adjuvant technologies and expanding vaccine accessibility initiatives to support long-term disease prevention strategies worldwide.

Additionally, in August 2025, Sanofi S.A. expanded its global immunization business through increased investments in pediatric and influenza vaccine production capabilities. The company also accelerated the development of next-generation vaccine platforms and strategic partnerships aimed at improving vaccine availability and strengthening infectious disease prevention globally.

Also, in July 2025, Johnson & Johnson advanced its vaccine development capabilities by expanding research activities related to viral vector technologies and infectious disease prevention. The initiative further supported the company’s strategy of strengthening global immunization programs and enhancing preparedness for emerging health threats.

Moreover, in June 2025, Moderna, Inc. expanded its mRNA vaccine pipeline through the development of new respiratory and oncology vaccine candidates utilizing advanced messenger RNA technologies. The company also focused on strengthening global manufacturing infrastructure and accelerating clinical development programs for next-generation vaccines.

Key Benefits

• The report provides quantitative analysis and estimations of the vaccines industry from 2025 to 2030, which assists in identifying the prevailing market opportunities.

• The study comprises a deep-dive analysis of the current and future vaccines market trends to depict prevalent investment pockets in the industry.

• Information related to key drivers, restraints, and opportunities and their impact on the vaccines industry is provided in the report. 

• Competitive analysis of the players, along with the vaccines market share is provided in the report.

• SWOT analysis and Porters Five Forces model is elaborated in the study.

• Value chain analysis in the market study provides a clear picture of roles of stakeholders.

Vaccines Market Key Segments

By Technology Platform

• Live Attenuated Vaccines

• Inactivated Vaccines

• Subunit and Recombinant Vaccines

• Polysaccharide and Conjugate Vaccines

• Toxoid Vaccines

• Viral Vector Vaccines

• Messenger RNA Vaccines

By Disease Indication

• Respiratory Diseases

  • Influenza Vaccines

  • Pneumococcal Vaccines

  • Covid 19 Vaccines

  • Respiratory Syncytial Virus Vaccines

• Pediatric Diseases

  • Diphtheria Tetanus Pertussis Vaccines

  • Measles Mumps Rubella Vaccines

  • Polio Vaccines

  • Varicella Vaccines

  • Rotavirus Vaccines

• Other Significant Diseases

  • Human Papillomavirus Vaccines

  • Meningococcal Vaccines

  • Hepatitis Vaccines

  • Herpes Zoster Vaccines

By Route of Administration

• Intramuscular Injection

• Subcutaneous Injection

• Oral Administration

• Intranasal Administration

By Target Population

• Pediatric Vaccines

• Adult and Adolescent Vaccines

• Geriatric Vaccines

By End User

• Public Sector Market

• Private Sector Market

By Region

• North America

  • The U.S.

  • Canada

  • Mexico

• Europe

  • The U.K.

  • Germany

  • France        

  • Italy        

  • Spain        

  • Denmark        

  • Netherlands        

  • Finland        

  • Sweden        

  • Norway        

  • Russia

  • Rest of Europe

• Asia-Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Indonesia

  • Singapore

  • Taiwan

  • Thailand

  • Rest of Asia-Pacific 

• RoW

  • Latin America

  • Middle East

  • Africa

Key Players

• Merck & Co., Inc. (MSD)

• Pfizer Inc.

• GlaxoSmithKline plc (GSK)

• Sanofi S.A.

• Johnson & Johnson

• Moderna, Inc.

• BioNTech SE

• CSL Seqirus

• Sinopharm Group / CNBG

• Novavax, Inc.

• Serum Institute of India Pvt. Ltd. (SII)

• Sinovac Biotech Ltd.

• Bharat Biotech International Ltd.

• Biological E. Limited (BE)

• Lonza Group AG

• Catalent, Inc.

• CanSino Biologics Inc.

• WuXi Vaccines

• Bavarian Nordic A/S

• Panacea Biotec Ltd.

Report Scope and Segmentation: